North America Diabetes Care Devices Market Industry Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

North America is the world's leading diabetes care devices market, benefiting from high diabetes prevalence, sophisticated reimbursement systems, and early adoption of advanced technology such as CGM and hybrid closed-loop insulin delivery. The regional market is estimated at USD 23.45 billion in 2025 and is on track to reach roughly USD 45-57 billion by the early 2030s. Public health agencies in the US and Canada track diabetes prevalence and healthcare expenditure but do not publish dedicated device-market size figures, so industry estimates come from private sector analyses.

• •Estimated 2025 value around USD 23.45 billion with a 9.2% CAGR.
• •United States accounts for the vast majority of regional revenue.
• •Includes CGMs, SMBG meters, insulin pumps, pens, and accessories.

Rising diabetes prevalence linked to obesity and aging populations is the fundamental demand driver, with the US Centers for Disease Control and Prevention reporting tens of millions of Americans living with the condition. Expansion of Medicare and commercial insurance coverage for CGM systems, including for non-insulin users, is removing cost barriers that previously limited adoption. Technological improvements such as smaller sensors, longer wear times, integrated pump-sensor systems, and smartphone connectivity are also accelerating both clinician prescription rates and patient uptake.

• •CDC data show continued growth in diagnosed diabetes prevalence in the US.
• •Broader insurance coverage of CGMs is opening access to millions of additional patients.
• •Automation, miniaturization, and smartphone integration are improving adherence and outcomes.

By device type, the market is split into CGM systems, self-monitoring blood glucose (SMBG) devices, insulin delivery devices (pumps and pens), and accessories, with CGM and insulin pumps representing the fastest-growing and highest-value segments. By end user, homecare settings dominate as patients increasingly self-manage with connected devices, while hospitals and diagnostic laboratories account for a smaller share. Within North America, the United States is by far the largest contributor, followed by Canada, with Mexico representing a smaller but rapidly developing segment driven by expanding healthcare access.

• •CGM is the fastest-growing device category, increasingly displacing traditional SMBG meters.
• •Insulin pumps and automated insulin delivery systems are expanding beyond type 1 diabetes into type 2.
• •United States holds the dominant share, with Canada and Mexico as smaller growth markets.

What are the recent trends and outlook?

The near-term outlook points to deeper integration of CGM data with insulin pumps, growing use of artificial intelligence and predictive algorithms for dose guidance, and expansion of CGMs into adjacent populations such as gestational, prediabetes, and wellness users. Reimbursement expansion, including potential US coverage for over-the-counter CGMs and broader type 2 indications, will be a key swing factor for growth rates. Looking further out, the market is expected to remain on a high-single-digit to low-double-digit growth trajectory, supported by ongoing technological innovation and continued policy support for diabetes management.

• •Automated insulin delivery (hybrid closed-loop) systems are becoming standard of care in type 1 diabetes.
• •CGM use in type 2 diabetes is expanding rapidly and is a major future growth lever.
• •AI-driven decision support and over-the-counter CGM access are emerging as the next industry milestones.